RASolute 302
The trial that nearly doubled survival in previously treated pancreatic cancer, presented in the ASCO 2026 plenary. The biggest result in the disease's history.
500 patients, 59 sites. Topline 13 April 2026; presented by Brian Wolpin (Dana-Farber) at the ASCO 2026 plenary (31 May) with simultaneous NEJM publication. Median OS 13.2 vs 6.7 months (HR 0.40, p<0.0001); PFS also significantly improved. NDA submission planned under a Commissioner's National Priority Voucher. First-line (RASolute 303) and adjuvant (RASolute 304) trials follow.
- Median 13.2 vs 6.7 months with Daraxonrasib compared with Chemotherapy (gemcitabine/nab-paclitaxel or mFOLFOX6); about 6.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 60 percent lower chance of the event at any given time (hazard ratio 0.4).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Metastatic PDAC after one prior line of chemotherapy: daraxonrasib vs investigator's choice chemotherapy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
460 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Daraxonrasib | — | 13.2 months | 0.4 | — | link |
| Chemotherapy (gemcitabine/nab-paclitaxel or mFOLFOX6) | — | 6.7 months |
Pages like this
not linked directly; found by shared links- ProductZoldonrasib
Shares RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable, Daraxonrasib, KRAS & RAS inhibitors, KRAS.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares Daraxonrasib, KRAS & RAS inhibitors, KRAS, The undruggable drivers.
- CompanyQuanta Therapeutics
Shares Daraxonrasib, KRAS & RAS inhibitors, KRAS, The undruggable drivers.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeaCovalent chemistry for the RAS mutations that still have no drug
Shares Daraxonrasib, KRAS & RAS inhibitors, KRAS, The undruggable drivers.
- ProductElironrasib
Shares KRAS & RAS inhibitors, KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- PairingG12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)
Shares Daraxonrasib, KRAS, Pancreatic ductal adenocarcinoma.
- CompanyRevolution Medicines
Shares Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers, Pancreatic ductal adenocarcinoma.